<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Connexin 43 is located in the cardiomyocyte sarcolemma and in the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane </plain></SENT>
<SENT sid="1" pm="."><plain>Sarcolemmal connexin 43 contributes to the spread of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>/reperfusion injury, whereas <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> connexin 43 contributes to cardioprotection </plain></SENT>
<SENT sid="2" pm="."><plain>We have now investigated the antiarrhythmic <z:chebi fb="0" ids="46761">dipeptide</z:chebi> ZP1609 (danegaptide), which is an analog of the connexin 43 targeting antiarrhythmic <z:chebi fb="7" ids="16670">peptide</z:chebi> rotigaptide (ZP123), in an established and clinically relevant experimental model of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion in pigs </plain></SENT>
<SENT sid="3" pm="."><plain>Pigs were subjected to 60 min <z:e sem="disease" ids="C0151814" disease_type="Disease or Syndrome" abbrv="">coronary occlusion</z:e> and 3 h reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>ZP1609 (n = 10) was given 10 min prior to reperfusion (75 μg/kg b.w. bolus i.v. + 57 μg/kg/min i.v. infusion for 3 h) </plain></SENT>
<SENT sid="5" pm="."><plain>Immediate full reperfusion (IFR, n = 9) served as control </plain></SENT>
<SENT sid="6" pm="."><plain>Ischemic postconditioning (PoCo, n = 9; 1 min LAD reocclusion after 1 min reperfusion; four repetitions) was used as a positive control of cardioprotection </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size (TTC) was determined as the end point of cardioprotection </plain></SENT>
<SENT sid="8" pm="."><plain>Systemic hemodynamics and regional myocardial blood flow during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> were not different between groups </plain></SENT>
<SENT sid="9" pm="."><plain>PoCo and ZP1609 reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size vs. IFR (IFR, 46 ± 4 % of area at risk; mean ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>; PoCo, 31 ± 4 %; ZP1609, 25 ± 5 %; both p &lt; 0.05 vs. IFR; ANOVA) </plain></SENT>
<SENT sid="10" pm="."><plain>There were only few <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> during reperfusion such that no antiarrhythmic action of ZP1609 was observed </plain></SENT>
<SENT sid="11" pm="."><plain>ZP1609 when given before reperfusion reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> size to a similar extent as ischemic postconditioning </plain></SENT>
<SENT sid="12" pm="."><plain>Further studies are necessary to define the mechanism/action of ZP1609 on connexin 43 in cardiomyocytes </plain></SENT>
</text></document>